Seizert Capital Partners’s Myriad Genetics MYGN Stock Holding History

Seizert Capital Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-105,128	Closed	-$3.22M	–	236
2016 Q2	$3.22M	Sell	105,128 -2,526	-2%	-$87.8K	0.12%	95
2016 Q1	$4.03M	Buy	107,654 +63,519	+144%	+$2.39M	0.14%	88
2015 Q4	$1.91M	Sell	44,135 -24,301	-36%	-$1.03M	0.06%	137
2015 Q3	$2.56M	Sell	68,436 -103,069	-60%	-$3.66M	0.08%	128
2015 Q2	$5.83M	Sell	171,505 -8,812	-5%	-$300K	0.15%	89
2015 Q1	$6.38M	Buy	180,317 +23,484	+15%	+$841K	0.16%	88
2014 Q4	$5.34M	Buy	156,833 +22,173	+16%	+$787K	0.11%	100
2014 Q3	$5.19M	Buy	134,660 +24,335	+22%	+$908K	0.1%	104
2014 Q2	$4.29M	Buy	110,325 +69,535	+170%	+$2.59M	0.09%	114
2014 Q1	$1.4M	Sell	40,790 -16,200	-28%	-$502K	0.03%	119
2013 Q4	$1.2M	Buy	+56,990	New	+$1.44M	0.03%	123

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Seizert Capital Partners's MYGN Position: Q3 2016 in Review

Seizert Capital Partners sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 105,128 shares — an estimated $3.22M sold.

Seizert Capital Partners first reported a position in MYGN in Q4 2013 and held it in 11 quarters. The position peaked at $6.38M in Q1 2015. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

Seizert Capital Partners reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
Seizert Capital Partners sold 105,128 Myriad Genetics shares in Q3 2016, an estimated $3.22M.
Seizert Capital Partners first reported a position in Myriad Genetics in Q4 2013 and held it in 11 quarters.
Seizert Capital Partners's Myriad Genetics position peaked at $6.38M in Q1 2015.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Seizert Capital Partners's 13F filing for Q3 2016, filed 9 Nov 2016.